Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Acute and continuation risperidone monotherapy in mania.

Eduard Vieta1, Esteve Brugué, José Manuel Goikolea

  • 1Bipolar Disorders Programme, Clinical Institute of Psychiatry and Psychology, Hospital Clinic, University of Barcelona, IDIBAPS, Spain. evieta@clinic.ub.es

Human Psychopharmacology
|January 13, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Corrigendum to "Functioning assessment short test for autism (FAST-A): a tool to evaluate adaptive functioning in autistic adults" [European Neuropsychopharmacology, 112, 112887].

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology·2026
Same author

Brain correlates of cognitive reserve in offspring of patients with schizophrenia or bipolar disorder.

European child & adolescent psychiatry·2026
Same author

Longitudinal Impact of Birthweight and its Polygenic Risk Score on Glucose and Antipsychotic-Induced Weight Gain in First Episode Psychosis.

Schizophrenia bulletin·2026
Same author

Functioning assessment short test for autism (FAST-A): a tool to evaluate adaptive functioning in autistic adults.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology·2026
Same author

20-year pharmacological treatment trajectories in a cohort of patients with bipolar disorder.

Psychiatry research·2026
Same author

Dot the i's and cross the t's: Can we get resilience in bipolar disorder right, please?

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology·2026
Same journal

Evaluation of Oculomotor Function Following Sleep Improvement With Lemborexant in Older Adults With Insomnia.

Human psychopharmacology·2026
Same journal

Relationship Between Clozapine Levels and Adverse Effects Evaluated by the GASS-C in Treatment-Resistant Schizophrenia.

Human psychopharmacology·2026
Same journal

ADHD, Psychotropic Medication and Pregnancy: The Influence of Maternal ADHD on Child Development-A Retrospective Cohort Study.

Human psychopharmacology·2026
Same journal

Long-Term Trends in Prescribing of Etizolam for Hypnotic Use in a Japanese University Hospital.

Human psychopharmacology·2026
Same journal

Verbal and Visuospatial Working Memory Performance During the CO<sub>2</sub> Challenge Model of Anxiety.

Human psychopharmacology·2026
Same journal

Serum Galectin-1 and Galectin-3 Levels and Their Relationship With Executive Functions and Memory in Patients With Major Depressive Disorder.

Human psychopharmacology·2026
See all related articles

Risperidone monotherapy effectively treats acute mania and prevents its return. This study found it well-tolerated, with no induced depression, though extrapyramidal side effects were noted.

Area of Science:

  • Psychiatry
  • Pharmacology

Background:

  • Bipolar disorder mania requires effective and safe treatment options.
  • Risperidone is an atypical antipsychotic used for various psychiatric conditions.

Purpose of the Study:

  • To evaluate the efficacy and safety of risperidone as a monotherapy for acute and continuation treatment of manic episodes in bipolar disorder patients.

Main Methods:

  • An open-label, 6-month, multicenter study involving 96 patients with acute mania (DSM-IV criteria).
  • Efficacy assessed using Young Mania Rating Scale (YMRS), Positive and Negative Syndrome Scale (PANSS), and Clinical Global Impressions (CGI) scale.
  • Safety evaluated via UKU Side Effect Rating Scale and Hamilton Depression Rating Scale (HDRS) to monitor for depressive switch.

Main Results:

Related Experiment Videos

  • 83.3% of patients completed the study.
  • Risperidone demonstrated highly significant improvements in YMRS, PANSS, and CGI scores from week 1 or 4 onwards (p<0.0001).
  • Extrapyramidal side effects showed an initial increase then a decrease by study end (p=0.027); no depressive symptoms were induced (HDRS improved, p<0.0001).

Conclusions:

  • Risperidone monotherapy is effective and well-tolerated for both acute and continuation treatment of mania.
  • Further confirmation through randomized, double-blind clinical trials is recommended.